BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38281751)

  • 1. [Central nervous system disorders secondary to histiocytoses: neurodegeneration with potential for improvement].
    Morimoto A; Sakamoto K; Kudo K; Shioda Y
    Rinsho Shinkeigaku; 2024 Feb; 64(2):85-92. PubMed ID: 38281751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
    Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
    J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
    Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
    Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.
    Milne P; Bigley V; Bacon CM; Néel A; McGovern N; Bomken S; Haniffa M; Diamond EL; Durham BH; Visser J; Hunt D; Gunawardena H; Macheta M; McClain KL; Allen C; Abdel-Wahab O; Collin M
    Blood; 2017 Jul; 130(2):167-175. PubMed ID: 28512190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.
    Hervier B; Haroche J; Arnaud L; Charlotte F; Donadieu J; Néel A; Lifermann F; Villabona C; Graffin B; Hermine O; Rigolet A; Roubille C; Hachulla E; Carmoi T; Bézier M; Meignin V; Conrad M; Marie L; Kostrzewa E; Michot JM; Barete S; Taly V; Cury K; Emile JF; Amoura Z;
    Blood; 2014 Aug; 124(7):1119-26. PubMed ID: 24894769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
    Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M
    Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed Langerhans Cell Histiocytosis and Erdheim-Chester Disease in a Girl: A Rare and Puzzling Diagnosis.
    Ocak S; Bayramoglu Z; Tugcu D; Karaman S; Unuvar A; Karakas Z
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):e375-e379. PubMed ID: 32097280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexistence of intracranial Langerhans cell histiocytosis and Erdheim-Chester disease in a pediatric patient: a case report.
    Kim S; Lee M; Shin HJ; Lee J; Suh YL
    Childs Nerv Syst; 2016 May; 32(5):893-6. PubMed ID: 26466952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
    Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
    Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathological and Clinical Findings in Cutaneous Manifestation of Erdheim-Chester Disease and Langerhans Cell Histiocytosis Overlap Syndrome Associated With the BRAFV600E Mutation.
    Liersch J; Carlson JA; Schaller J
    Am J Dermatopathol; 2017 Jul; 39(7):493-503. PubMed ID: 27898473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
    Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J
    J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of
    Razanamahery J; Godot A; Leguy-Seguin V; Samson M; Audia S; Bonnotte B
    Front Immunol; 2023; 14():1260193. PubMed ID: 37809108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in the Histopathologic Diagnosis of Histiocytic Neoplasms.
    Rech KL; He R
    J Natl Compr Canc Netw; 2021 Nov; 19(11):1305-1311. PubMed ID: 34781270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
    Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
    Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
    JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.
    Hyman DM; Diamond EL; Vibat CR; Hassaine L; Poole JC; Patel M; Holley VR; Cabrilo G; Lu TT; Arcila ME; Chung YR; Rampal R; Lacouture ME; Rosen N; Meric-Bernstam F; Baselga J; Kurzrock R; Erlander MG; Janku F; Abdel-Wahab O
    Cancer Discov; 2015 Jan; 5(1):64-71. PubMed ID: 25324352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Status of Langerhans cell histiocytosis in children and adults].
    Kudo K
    Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.
    McClain K
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):395-399. PubMed ID: 33275721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of neuroimaging features of histiocytic neoplasms with central nervous system involvement: a retrospective study of 121 adult patients.
    Fan X; Liu T; Zhang Z; Sun J; Niu N; Mao C; Wang F; Li J; Zhou D; Cao X; Jin Z; Feng F
    Eur Radiol; 2023 Nov; 33(11):8031-8042. PubMed ID: 37191919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease.
    Dai JW; Lin H; Chang L; Li J; Zhou DB; Cao XX
    Ann Hematol; 2023 Dec; 102(12):3335-3343. PubMed ID: 37922006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.